Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — H.C. Wainwright & Co. 22nd Annual Global Investment Conference (September 2020)
29 slides from Evofem Biosciences's conference presentation, Sep 14, 2020
Slide 1: Revolutionizing Women's Sexual and Reproductive Health
Exhibit 99.1 Revolutionizing Women’s Sexual and Reproductive Health Saundra Pelletier, CEO H.C. Wainwright & Co. 22nd Annual Global Investment Conference September 14, 2020 Nasdaq: EVFM For investor discussions only. 1 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” ”will,” “should,” “expect,
Slide 3: About Evofem Biosciences
About Evofem Biosciences A Commercial-Stage Biopharmaceutical Company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health First-in-Class1 Experienced Unmet FDA-Approved Execution Need Contraceptive Team 1. Phexxi™ (lactic a
Slide 4: Phexxi is Now Available!!!
pHexxi is Now Available!!! 4 For investor discussions only. 4 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.
Slide 5: Phexxi First-in-class Vaginal pH Modulator
Phexxi™ First-in-class Vaginal pH Modulator1 • Maintains vaginal pH level of 3.5 – 4.5 even in the presence of semen 2,3,4,5 • Inhibits sperm motility • Non-hormonal, female- controlled, on-demand vaginal gel with bio-adhesive properties • First contraceptive innovation in decades 1. Phexxi™ (lactic
Slide 6: Phexxi Now Available
Phexxi™ Now Available Indication: For the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.1 Innovative MOA: pH modulating effect2 Favorable Safety Profile: Only 1.6% discontinuation rate due to AEs Unmet Need – 21 million woman at risk for
Slide 7: HCPs Recognize the Unmet Need for Prescription Non-Hormonal Options
HCPs Recognize the Unmet Need for Prescription Non-Hormonal Options Baseline Post-allocation % % Market Research Oral Contraceptives (Regular, 28-day) 30% 26% Survey Highlights PHEXXI™ n/a 15% Hormonal IUD 12% 11% HCPs lowered allocation Condom 10% 8% for hormonal options Injectable 8% 7% from 74% t
Slide 8: HCP Omnichannel Strategy
HCP Omnichannel Strategy A Comprehensive Digital Promotional Programs Model to Drive Brand Awareness Educational Videos ResourcesPatient MOA Video HCP Website Rep Leave Behind Leave Rep For investor discussions only. 8 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.
Slide 9: Journal Ads and Banners
Journal Ads and Banners For investor discussions only. 9 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.
Slide 10: Reaching HCPs with "Best in Class" Sales Team
Reaching HCPs with “Best in Class” Sales Team Resourced to be scalable, adaptable, flexible; efficiently designed to support our strategy 70 Women’s Health sales reps and regional managers • Average experience of 15 years in Pharma with 8 of those years being in women’s health o Existing relationshi
Slide 11: The Time is Right for Phexxi
The Time is Right for Phexxi In the US today, there are 21 million women at risk for pregnancy who are NOT using hormonal contraception1 1. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015- 2017. NCHS Data Brief. 2018; 327: 1-14. 1111 ©©2019 2020 EvofemEvo
Slide 12: Consumer Omnichannel Strategy
Consumer Omnichannel Strategy A Comprehensive Digital Promotional Programs Model to Drive Brand Awareness For investor discussions only. 12 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.
Slide 13: For Launch our Visual Approach is Bold and Breaks the Category Conventions
For Launch our Visual Approach is Bold and Breaks the Category Conventions to Ensure Phexxi Stands Out For investor discussions only. 13 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.
Slide 14: Strategic and Diverse Media Activation Plan
Strategic and Diverse Media Activation Plan SEARCH ADVOCACY PROGRAMMATIC DISPLAY ENDEMIC DISPLAY LIFESTYLE DISPLAY AUDIO ADS SPONSORED CONTENT POINT OF CARE For investor discussions only. 14 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.
Slide 15: Priming the Consumer Market and Amplifying the Brand
Priming the Consumer Market and Amplifying the Brand through Notable Outlets and Influential Voices Ongoing Social Content & Sponsored Content Executive Visibility Social Media Placements Communications Support Influencer Engagement Sexual Satisfaction Poll Pre-Launch Launch Post-Launch (August 20’)
Slide 16: Priming the Consumer Market and Amplifying the Brand
Priming the Consumer Market and Amplifying the Brand through Notable Outlets and Influential Voices For investor discussions only. 16 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.
Slide 17: Phexxi Concierge Experience: An Innovative Digital Marketing Solution
Phexxi Concierge Experience: An Innovative Digital Marketing Solution For investor discussions only. 17 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.
Slide 18: Phexxi Concierge Experience: An Innovative Digital Marketing Solution
Phexxi Concierge Experience: An Innovative Digital Marketing Solution An innovative support program Caters to women at any point in their birth control journey Provides options and easy access to Phexxi Provides information and data about Provides information on our Phexxi needed to make an informed
Slide 19: Talk to a Doctor About Phexxi Now…
Talk to a Doctor About Phexxi Now… For investor discussions only. 19 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.
Slide 20: The Copay Assistance Program Helps Eligible Patients Access Phexxi
The Copay Assistance Program Helps Eligible Patients Access Phexxi Prescriptions • Designed to mitigate coverage gaps that occur while payers are making final coverage decisions • Must have commercial insurance • Pay $0 OOP for first fill • Pay as little as $30 OOP for subsequent fills • Prior autho
Slide 21: Mail-order Pharmacy Increases Patient Options
Mail-order Pharmacy Increases Patient Options Ensures coverage Delivers drugs Provides with prior directly to patients’ prescription support authorization homes services support Partnering with a mail-order pharmacy will give patients more options in the COVID environment For investor discussions on
Slide 22: At Launch 55% of All Commercial Lives Covered
At Launch 55% of All Commercial Lives Covered • Phexxi established in two major drug compendia as the first-and-only “Vaginal pH Modulator”1 • To date no insurer has blocked Phexxi following a clinical review • 55% of all commercial lives at launch (i.e. $0 copay, preferred, and/or non-preferred tie
Slide 23: Women Are Demanding More…
Women Are Demanding More… HAD ENOUGH WITH HORMONES PREFERS NATURAL / ORGANIC HIGHLY INFORMED IN A COMMITTED RELATIONSHIP AVOIDS LONG-TERM BC OPTIONS RESEARCH + REGULAR HCP VISITS …they are tired of figuring out the only difference between new hormonal contraception options and ones of past is changi
Slide 24: EVO100 for Prevention of Chlamydia and Gonorrhea in Women
EVO100 for Prevention of Chlamydia and Gonorrhea in Women AMPREVENCE Phase 2b Trial: Incidence of C/G Statistically Significant Results Continues to Rise • US Chlamydia: ~1.8 10 9.8% million reported cases1 8 50% Relative Risk Reduction 6 • US Gonorrhea: ~580,000 4.9% million reported cases1 4 78% 3
Slide 25: EVO100 for Prevention of Chlamydia and Gonorrhea in Women: Timeline
EVO100 for Prevention of Chlamydia and Gonorrhea in Women: Timeline 2020 Q4 2022 2023 Initiate Pivotal Top-Line Phase 3 Results1 Potential Phase 3 Trial Potential NDA submission2 US Approval • FDA Fast Track designation for prevention of chlamydia in women • FDA QIDP designation for prevention of go
Slide 26: Financial Overview
Financial Overview Shares outstanding: 81.3M1 Warrants outstanding: 10.4M2 (weighted average exercise price $4.54) Unrestricted cash of $123.6M at June 30, 2020 • Includes $136M in aggregate gross proceeds from two financing transactions closed in Q2 2020 • Runway into Q2 2021 based on projected exp
Slide 27: Our Time is Now!
Our Time is Now! pHirst major contraceptive innovation in decades – Non-hormonal, female-controlled, on-demand, vaginal pH modulator gel contraceptive Potential to be first and only FDA- EVO100 approved prescription product for Granted fast-track & prevention of urogenital chlamydia and QIDP designa
Slide 28: Phexxi Addressable Market & Peak Revenue Potential
Phexxi Addressable Market & Peak Revenue Potential US Contraceptive Phexxi Annual Gross Revenue Opportunity 1 Market: 69M Women by Market Segment Primary Targets • 6.0M barrier methods • 2.7M withdrawal 3.5% - 4.5%2 = 340k - 440k users 9.7M Non-Rx • 1.0M periodic abstinence Contraceptive $640M - $82
Slide 29: ®
® 29 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.